CD38 and infection: Early initiation of antiretroviral therapy during the acute infection phase (Fiebig I/II) can reduce activation markers (percentage of mucosal and peripheral CD38+/HLA-DR+/CD8+ T cells) to the levels observed in uninfected individuals.